Table 5 The diagnostic performance of tRF-23-Q99P9P9NDD, CEA, CA199 and CA724 in differentiating GC patients from gastritis patients
| Â | SEN (%) | SPE (%) | ACCU (%) | PPV (%) | NPV (%) |
|---|---|---|---|---|---|
tRF-23-Q99P9P9NDD | 0.60 (74/124) | 0.74 (37/50) | 0.64 (111/174) | 0.85 (74/87) | 0.43 (37/87) |
CEA | 0.60 (74/124) | 0.86 (43/50) | 0.67 (117/174) | 0.91 (74/81) | 0.46 (43/93) |
CA199 | 0.44 (55/124) | 0.80 (40/50) | 0.55 (95/174) | 0.85 (55/65) | 0.37 (40/109) |
CA724 | 0.53 (66/124) | 0.84 (42/50) | 0.62 (108/174) | 0.89 (66/74) | 0.42 (42/100) |
tRF-23-Q99P9P9NDD + CEA | 0.66 (82/124) | 0.68 (34/50) | 0.67 (116/174) | 0.84 (82/98) | 0.45 (34/76) |
tRF-23-Q99P9P9NDD + CA199 | 0.67 (83/124) | 0.60 (30/50) | 0.65 (113/174) | 0.81 (83/103) | 0.42 (30/71) |
tRF-23-Q99P9P9NDD + CA724 | 0.76 (94/124) | 0.66 (33/50) | 0.73 (127/174) | 0.85 (94/111) | 0.52 (33/63) |
tRF-23-Q99P9P9NDD + CEA + CA199 | 0.70 (87/124) | 0.56 (28/50) | 0.66 (115/174) | 0.80 (87/109) | 0.43 (28/65) |
tRF-23-Q99P9P9NDD + CEA + CA724 | 0.80 (99/124) | 0.60 (30/50) | 0.74 (129/174) | 0.83 (99/119) | 0.55 (30/55) |
tRF-23-Q99P9P9NDD + CEA + CA199 + CA724 | 0.81 (101/124) | 0.48 (24/50) | 0.72 (125/174) | 0.80 (101/127) | 0.51 (24/47) |